Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
TTHX1114 Guards Against Ferroptosis in Primary Rabbit Corneal Endothelial Cells
Author Affiliations & Notes
  • Jessica Weant
    Trefoil Therapeutics, San Diego, California, United States
  • Anna Stuhlfire
    Trefoil Therapeutics, San Diego, California, United States
  • Lindsey Myers
    Trefoil Therapeutics, San Diego, California, United States
  • Sarah Pizzuto
    Trefoil Therapeutics, San Diego, California, United States
  • Tyler Todd
    Trefoil Therapeutics, San Diego, California, United States
  • Grace Duffey
    Trefoil Therapeutics, San Diego, California, United States
  • David Eveleth
    Trefoil Therapeutics, San Diego, California, United States
  • Footnotes
    Commercial Relationships   Jessica Weant Trefoil Therapeutics, Code E (Employment); Anna Stuhlfire Trefoil Therapeutics, Code E (Employment); Lindsey Myers Trefoil Therapeutics, Code E (Employment); Sarah Pizzuto Trefoil Therapeutics, Code C (Consultant/Contractor); Tyler Todd Trefoil Therapeutics, Code E (Employment); Grace Duffey Trefoil Therapeutics, Code E (Employment); David Eveleth Trefoil Therapeutics, Code E (Employment), Trefoil Therapeutics, Code I (Personal Financial Interest), Trefoil Therapeutics, Code O (Owner)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4147. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Weant, Anna Stuhlfire, Lindsey Myers, Sarah Pizzuto, Tyler Todd, Grace Duffey, David Eveleth; TTHX1114 Guards Against Ferroptosis in Primary Rabbit Corneal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4147.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Fuchs’ Dystrophy, cataract surgery, and corneal edema are associated with oxidative stress. tert-Butyl hydroperoxide (tBHP) damage affects cell DNA, mitochondria, gene expression profiles, apoptotic signaling, and causes death by ferroptosis. Herein we interrogate a treatment model where our drug, a synthetic analog of FGF1 - TTHX1114 (TTHX), safeguards primary rabbit corneal endothelial cells (pRCEnCs) from ferroptosis.

Methods : pRCEnCs were harvested from Descemet’s Membranes. Cells were subjected to oxidative stress via 50µM tBHP insult for 2 hours and received either 50ng/mL TTHX or serum free media. The MTT assay was used to quantify cell viability. Cells were fixed, permeabilized, and stained with TUNEL, ZO-1, and Hoechst. Cell density and TUNEL counts were performed with ImageJ. RNA extraction and library prep performed with Illumina NEBNext Ultra II RNA Library Prep Kit. Sequencing libraries were clustered on one flow cell and sequenced with Illumina HiSeq. Analysis performed by ROSALIND and DAVID.

Results : MTT absorbance data show loss of pRCEnC viability and loss of cell metabolic function after 50µM tBHP insult. TTHX treatment protects and rescues cell viability and metabolic function. The MTT signal is not significantly different from un-insulted growth media baseline control. Fluorescent stained cell images and cell counts show tBHP insulted TTHX treated cells have clearly defined and regular ZO-1 boarders and no TUNEL stain was observed. TUNEL was observed in other cell protection and rescue treatments. TTHX cell counts: 142.7 ± 54.1. Growth media cell counts: 137.7 ± 17.8. tBHP insult only condition could not be counted for cell density due to cell death, but definite TUNEL staining was present. RNA Seq gene expression shows 50µM tBHP 2-hour insult caused strong upregulation in essential and associated ferroptosis genes: ACSL4, HMOX1, GCL, SLC7A11, SLC3A, and Ferroportin. TTHX treatment blocks upregulation of those genes and promotes enrichment of proliferative pathways and pathways related to oxidative stress. Anti-ferroptotic genes are upregulated in TTHX treated cells, but ferroptosis is not enriched.

Conclusions : By reducing cell loss and DNA breakage; perturbing ferroptotic processes; and upregulating cell survival, proliferation, and anti-ferroptosis genes, a pre/post treatment with 50ng/mL TTHX is ideal for maximizing protection and rescue of pRCEnCs from oxidative stress and cell death.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×